natgillin/translations-raw huggingface dataset:
Netupitant for use according to claims 1-23, said use comprising treating nausea and vomiting in response to highly emetogenic chemotherapy during the acute phase, or in response to highly emetogenic chemotherapy during the delayed phase, or in response to moderately emetogenic chemotherapy during the acute phase, or in response to moderately emetogenic chemotherapy during the delayed phase. 
Netupitant za uporabu u skladu s patentnim zahtjevima 1-7, obuhvaća liječenje mučnine 1 povraćanja kao odgovora na vrlo emetogenu kemoterapiju za vrijeme akutne faze, ili kao odgovor na vrlo emetogenu kemoterapiju tijekom odgođene faze.
After refluxing the reaction mixture for 1.5 hours, it was cooled to room temperature and concentrated in vacuo. 
Nakon refluksiranja reakcijske smjese tijekom jednog i pol sata, ona se ohladi na sobnu temperaturu i koncentrira in vacuo.
about 55% to about 90% by weight of polysiloxane elastomer; and 
od 55 % do 90 % polisiloksan elastomera u odnosu na masu i
or R2 and R3 combine to form, with the nitrogen to which they are attached, 
ili se R2 i R3 kombinira kako bi, s dušikom na kojeg su vezani, tvorili [image];
When placed horizontally on a piece of tissue paper, the article did not ignite or even scorch the tissue paper. 
Kada se stavi vodoravno na komad tkivnog papira proizvod nije palio niti čak nagorio tkivni papir.
mg (1.50% w/w) of hydroxypropyl methyl cellulose (6 cps) were dissolved in 35 ml of purified water pre-heated to 70° C. and then after cooled, and is used as the granulating solution to prepare granules by mixing with nebivolol hydrochloride adsorbed blend till the mass of required consistency was obtained. 
Postupak 3,45 mg (1,50 % w/w) hidroksipropil metil celuloze (6 cps) otopljeno je u 35 ml pročišćene vode prethodno zagrijane na 70 *C te zatim poslije ohlađena, te je rabljena kao otopina za granuliranje da bi se dobile granule pomoću miješanja s mješavinom s adsorbiranim nebivolol hidrokloridom dok nije dobivena masa tražene konzistencije.
The anti-CSF-1R antibody according to claim 1 or 2, having a binding affinity for human CSF-1R of 10pM or less than 10pM. 
Anti-CSF-1R antitijelo prema patentnom zahtjevu 1 ili 2 naznačeno time da ima afinitet vezanja za ljudski CSF-1R od 10 pM ili manji od 10 pM.
The deprotection according to method a) was performed by standard techniques, known to the persons skilled in the art and detailed in the textbook Protective Groups in Organic Synthesis, Greene and Wuts, Wiley Interscience, (1991), ISBN 0471623016. 
Deprotekcija prema načinu a) ostavljena je standardnom tehnikom, poznatom stručnjacima i opisana u udžbeniku Protective Groups in Organic Synthesis, Greeene i Wuls, Wiley Interscience (1991.), ISBN 047823016.
A process to make a sourdough from a microencapsulated bacterial consortium for gluten degradation, in combination with a proteolytic enzyme of bacterial origin and a proteolytic enzyme of fungal origin, comprising the following steps: 
Postupak proizvodnje kiselog tijesta iz mikroenkapsuliranog bakterijskog konzorcija prema zahtjevu 1, u kombinaciji s proteolitičkim enzimom bakterijskog porijekla i proteolitičkim enzimom gljivičnog porijekla, koji sadrži sljedeće korake: i)
Examples of suitable therapies for treatment of sleeping disorders for use in combination with the compounds of the present invention include melatonin analogs, melatonin receptor antagonists, ML 1 B agonists, GABA receptor modulators; NMDA receptor modulators, histamine-3 (H3) receptor modulators, dopamine agonists and orexin receptor modulators. 
Primjeri prikladnih terapeutika za liječenje poremećaja spavanja za primjenu u kombinaciji sa spojevima prikazanog izuma uključuju analoge melatonina, antagoniste melatonin receptora, ML 1 B agoniste, modulatore GABA receptora, modulatore NMDA receptora, modulatore histamin-3(H3) receptora, agoniste dopamina ili modulatore oreksin receptora.
A method for treatment of an autoimmune disease which comprises administering to a patient in need thereof, an effective amount of a compound of claim 1, wherein the autoimmune disease is selected from the group consisting of multiple sclerosis, psoriasis, intestine inflammatory disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis and polyarthritis, local and systemic scleroderma, systemic lupus erythematosus, discoid lupus erythematosus, cutaneous lupus, dermatomyositis, polymyositis, Sjogren's syndrome, nodular panarteritis, autoimmune enteropathy, and proliferative glomerulonephritis. 
Uporaba spoja prema bilo kojem od zahtjeva od 1 do 11, naznačena time da za proizvodnju lijeka namijenjenog liječenju autoimunih bolesti poput multiple skleroze, psorijaze, upalne bolesti crijeva, hemoragičkog rektokolitisa, Chronove bolesti, reumatskog artiritisa i poliartritisa, lokalizirane i sistematske sklerodermije, eritemski diseminiranog lupusa, eritemskog diskoidnog lupusa, kožnog lupusa, dermatomiozitisa, polimiozitisa, Sjorgenovog sindroma, čvorastog panarteritisa, autoimune enteropatije kao i proliferativnog glomeruloneftitisa.
Membranes are incubated with 50 ul [125I] His5, D-Tyr6 GnRH (0.2 nM final concentration) and 50 ul of small molecule competitors at concentrations ranging from 30 pM to 10 uM for a total volume in each well of 200 ul. 
Membrane su inkubirane s 50 ul ['"I]-His,D-Tyr"-GnRH (konačna koncentracija 0,2 nM) odnosno 50 ul niskomolekulskih kompetitora, u rasponu koncentracija od 30 pM do 10 uM, u ukupnom volumenu u svakoj jažici od po 200 ul.
providing a virgin Ziegler-Natta catalyzed polyethylene resin, wherein the virgin polyethylene resin has a multimodal distribution and comprises at least two polyethylene fractions A and B, fraction A having a higher molecular weight and lower density than fraction B, wherein fraction A has a HL275 of at least 0.1 g/10 min and of at most 4 g/10 min as determined according to ISO 1133, condition G, at 190°C and under a load of 21.6 kg except that a die of 2.75 mm broad was used and has a density of at least 0.920 g/cm3 and of at most 0.942 g/cm3; and the virgin polyethylene resin having an HLMI of 5 to 75 g/10 min as determined according to ISO 1133, condition G, at 190°C and 21.6 kg, a density ranging from 0.945 to 0.960 g/cm3, the density being determined according to ASTM 1505 at a temperature of 23°C; 
- < Pribava Ziegler-Natta katalizirane neobrađene polietilenske smole, naznačeno time da polietilenska smola multimodalne raspodjele 1 sadrži najmanje dvije polietilenske frakcije A 1 B, frakcija A sa većom molekularnom težinom i manjom gustoćom od frakcije B, naznačeno time da frakcija A ima HL275 od najmanje 0.1 g/10 mini od najviše 4 g/10 min kako je utvrđeno prema ISO 1133, uvjet G, na 190"C 1 pod opterećenjem od 21.6kg osim što je korišten kalup širine 2.75mm i gustoće od najmanje 0.920 g/ems 1 od najviše 0.942 g/cm3; i neobrađene polietilenske smole koja ima HLMI od 5 do 75 g/10 min kako je utvrđeno prema ISO 1133, uvjet G, na 190% i 21.6kg, gustoće između 0.945 do 0.960 g/cm5 utvrđene prema ASTM 1505 na temperaturi od 23?C;
Various concentrations of antagonists are prepared in 0.1% BSA/FLIPR buffer in a third 96-well plate. 
Različite koncentracije antagonista u 0,1 % BSA/FLIPR puferu pripravljene su na trećoj ploči s 96 jažica.
The system of claim 1 wherein the pump is a peristaltic pump. 
Sustav prema zahtjevu 1, naznačen time što je pumpa peristaltička pumpa.
R6 hydroxyl, OP2, R7COO or an ether functionality such as an O-methylthiomethyl or other hetero 
hidroksil, OP», R;CO00 1li eterska funkcionalna skupina kao što je O-metiltiometil ili drugi hetero supstituirani eteri
sensing physical conditions at each nozzle along an inside of the cylindrical body; and the step of calculating comprises the step of: 
očitavanje fizikalnih uvjeta kod svake mlaznice (131) duž unutrašnjosti cilindričnog tijela (110); te korak izračunavanja sadrži korak:
(2B) (a) a conjugate of a carrier protein and the capsular saccharide of H. influenzae type B (Hib), and optionally a conjugate of a carrier protein and Vi saccharide of Salmonella typhi 
(ii) vezikulu od vanjske membrane bakterije Neisseria meningitidis tip B (MenB) ili LOS ili konjugirani saharid iz kapsule MenB; (ili) saharid Vi iz bakterije Salmonella typhi, konjugiran s proteinskim nosačem; ili
A polypeptide comprising an amino acid sequence that has an overall sequence identity to SEQ ID NO: 2 of at least 80%, wherein: the sequence identity of said amino acid sequence to SEQ ID NO: 2 is more than 80% at the backbone regions of SEQ ID NO: 2; and the sequence identity of said amino acid sequence to SEQ ID NO: 2 is less than 80% at the loop regions of SEQ ID NO: 2, wherein the amino acid sequence comprises a backbone, in eight backbone regions, and seven loop regions, one between each part of backbone sequence. 
Polipeptid koji sadrži aminokiselinsku sekvencu koja ima ukupni identitet sa sekvencom SEQ ID NO: 2 od najmanje 80%, naznačen time da: je identitet sekvence navedene aminokiselinske sekvence sa SEQ ID NO: 2 veći od 80% u regijama glavnog lanca SEQ ID NO: 2; i identitet sekvence navedene aminokiselinske sekvence sa SEQ ID NO: 2 manji od 80% u regijama petlji sekvence SEQ ID NO: 2, u kojima aminokiselinska sekvenca sadrži glavni lanac s osam regija glavnog lanca i sedam regija petlje, po jednu između svakog dijela sekvence glavnog lanca.
Wells were washed once with 200 ul PBS/Tween 20 (made by adding 1 sachet of PBS/Tween dry powder (Sigma, No. 
Bunarići se jedanput isperu pomoću ispirača mikrotitarskih pločica, koristeći otopinu 200 ul PBS / Tween 20 (napravljena dodatkom 1 vrećice PBS / Tween suhog praha (Sigma, No.
Then, 200 mL of water were added and the mixture was hydrolyzed by boiling for 6 hours. 
Potom se doda 200 ml vode i smjesa hidrolizira vrenjem tijekom 6 sati.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) cyprodinil. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) fludioksonil.
Also the density of uterine oxytocin receptors increases significantly by >100 fold during pregnancy and peaks in labour (pre-term and term). 
Isto tako, gustoća uterinih (materničnih) oksitocinskih receptora značajno poraste, > 100 puta, tijekom trudnoće, a vrhunac je tijekom porođaja (prijevremenog i pravovremenog).
The compound of claim 1, characterized by formula VI: 
2. Spoj iz zahtjeva 1, okarakteriziran formulom VI:
Charged groups are classified according to type (cationic and anionic) and strength (strong or weak); the charge characteristics of strong ion exchange media do not change with pH, whereas with weak ion exchange media, sample loading capacity can change owing to loss of charge at varying pH, preventing protein binding (Amersham Biosciences B 1998). 
Nabijene se skupine klasificiraju prema tipu (kationske i anionske) i snazi (jake ili slabe); svojstva naboja jakih medija za ionsku izmjenu ne mijenjaju se sa promjenom u pH, dok se kod slabih medija za ionsku izmjenu kapacitet nanošenja uzorkamože promjeniti zbog gubitka naboja do kojeg dolazi promjenom pH vrijednosti, čime se sprečava vezanje proteina (Amersham Biosciences B 1998).
According to one preferred embodiment of the inventive process, the at least one water soluble non-polymeric organic and/or inorganic weak acid and/or hydrogen salt of said at least one water soluble non-polymeric organic and/or inorganic weak acid has a molecular weight of less than 1 000 g/mol, preferably less than 750 g/mol and more preferably less than 500 g/mol. 
Postupak prema bilo kojem od zahtjeva 1 do 4, naznačen time da najmanje jedna u vodi topiva ne-polimerna organska i/ili anorganska slaba kiselina iili vodikova sol navedene barem jedne u vodi topive ne-polimerne organske i/ili anorganske slabe kiseline ima molekularnu težinu od manje od 1000 g/mol, poželjno manje od 750 g/mol i još poželjnije manje od 500 g/mol.
(c1) CDR H3: Tyr Arg Asp Tyr Asp Tyr Ala Met Asp Tyr (SEQ ID NO: 3) and the amino acid sequences of the complementary determining regions (CDRs) of the light chain are 
(Cc) CDR H3: Tyr Arg Asp Tyr Asp Tyr Ala Met Asp Tyr (SEQ ID NO: 3) i aminokiselinski sljedovi regija koje određuju komplementarnost (CDR) od lakog lanca:
A distributed computing system (1) for synchronizing data-sets stored on different communication devices which are connected via communication links, comprising 
Distribuirani računalni sustav (1) za sinkroniziranje podatkovnih nizova pohranjenih u različitim komunikacijskim uređajima međusobno povezanim komunikacijskim vezama, naznačen time što sadrži
Vinification tank according to any one of the preceding claims, wherein the nozzles have a substantially open L shape and in particular their outlet is arranged at an opening angle of between 110° and 180°, with respect to the perpendicular to the side wall of the container from which the nozzle projects internally, preferably with an opening angle comprised between 115° and 170°, more preferably between 115° and 150°. 
Vinifikacijski spremnik i uređaj prema patentnom zahtjevu 1, gdje spomenute mlaznice imaju u osnovi oblik otvorenog slova L. Vinifikacijski spremnik i uređaj prema patentnom zahtjevu 2, gdje ispust svake mlaznice čini kut otvora u rasponu od 115° do 170° sa okomitom stranicom spremnika iz koje mlaznica ulazi prema unutra.
In vitro assay examples. 
Primjeri pokusa in vitro
1 shows a rock bolt in accordance with the invention. 
prikazuje sidro u stijeni u skladu s izumom.
A compound of the following formula: 
Spoj slijedeće formule: gdje
In certain embodiments, the carbohydrate (and optionally, an antioxidant) is present in an amount sufficient to inhibit the reaction of a free thiol on a first molecule of the GCB protein with a free thiol on a second molecule of the GCB protein to form an aggregate. 
Farmaceutska kompozicija prema zahtjevu 1, pri čemu je ugljikohidrat prisutan u količini koja je dovoljna za inhibiranje reakcije slobodnog tiola na prvoj molekuli proteina sa slobodnim tiolom na drugoj molekuli proteina kojom se formira agregat.
transmitting a plurality of said characteristic signal patterns (DEL) at different timings and/or in different portions of the spectrum and/or spread spectrum modulated with different spreading codes; and 
- < za prijenos mnoštva navedenih karakterističnih oblika signala (DEL) u različitim odabirima vremena i/ili u različitim dijelovima spektra i/ili u širokom spektru moduliranom s različitim zaporkama širenja; te
The solid form of claim 1, characterized by three or more peaks expressed in 2-theta±0.2 at about 6.1, 12.2, 14.5, 22.3, and 31.8 degrees in an X-ray powder diffraction pattern obtained using Cu K alpha radiation. The solid form of claim 1, characterized as having an X-ray powder diffraction pattern substantially the same as that shown in FIG. 1 c. 
ii) koji se odlikuje s jednim ili više vrhova izraženim u 2-theta ± 0,2 na oko 6,1; 12,2; 14,5; 22,3 i 31,8 stupnjeva u rendgenskom difrakcijskom prahu dobivenom primjenom Cu K alfa zračenja; iii) koji se odlikuje time da ima rendgenski difrakcijski prah u osnovi isti kao onaj prikazan na slici Slici 1c;
GnRH is released from the hypothalamus and acts on the pituitary gland to stimulate the biosynthesis and release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). 
GnRH se otpušta iz hipotalamusa i djeluje na hipofizu, stimulirajući biosintezu i otpuštanje luteinizirajućeg hormona (LH) i folikulostimulirajućeg hormona (FSH).
separating the compound of Formula VIb, or a salt thereof, from the compound of Formula VIa, or a salt thereof. 
razdvajanje spoja formule VIb, ili njegove soli, od spoja formule VIa, ili njegove soli.
A pharmaceutical dosage form which comprises a melt-processed mixture of at least one active ingredient, at least one pharmaceutically acceptable polymer and a solubilizing composition, the solubilizing composition comprising (i) at least one tocopheryl compound having a polyalkylene glycol moiety and (ii) at least one alkylene glycol fatty acid monoester or mixture of alkylene glycol fatty acid mono- and diester. 
Farmaceutska doza koja sadrži smjesu taline od barem jednog aktivnog sastojka, barem jednog farmaceutski prihvatljivog homopolimera ili kopolimera N-vinilpirolidona i otapajuća smjesa, pri čemu je aktivni sastojak prisutan kao čvrsta disperzija, a otapajuća smjesa sadrži (i) barem jedan tokoferol sastojak koji odgovara formuli (I) [image]
The system of aspect 15 wherein the ablation probe is further adapted and configured to be advanced through a urethral wall and into an apex of the prostate lobe. 
Sustav prema zahtjevu 1, naznačen time da je sonda za ablaciju (120) nadalje podešena i konfigurirana za postavljanje kroz stjenku uretre i u vrh režnja prostate.
For culturing cells, in the past the culture medium was supplemented with serum, which serves as a universal nutrient for the growth and maintenance of all mammalian cell lines that produce biologically active products. 
U prošlosti je medij za uzgoj stanica bio obogaćen serumom koji je služio kao univerzalni nutrijent za uzgoj i održavanje svih staničnih linija porijeklom od sisavaca koje stvaraju biološki aktivne proizvode.
-SOR3a, -SO2R3a, and -SO2NR3aR3b, wherein R3a, and R3b are independently selected from the group consisting of 
(20)-SO+NRa,R2, gdje Ra, i Ray su neovisno odabrani iz skupine koja sadrži (1) vodik,
Other derivatives include aliphatic esters of the carboxyl groups, amides of the carboxyl groups by reaction with ammonia or with primary or secondary amines, N-acyl derivatives of free amino groups of the amino acid residues formed with acyl moieties (e.g. 
Drugi derivati uključuju alifatksc cstere karboksilnih skupina, amida karboksilnih skupina u reakciji sa amonijakom ili primarnim ili sekundarnim aminima, N-acilne derivate slobodnih aminoskupina aminokiselinskih ostataka stvorene sa acil-nim skupinama (npr.
an absorbance determining section for determining any one of a plurality of average values calculated by the average value calculating section to be absorbance for performing a sample analysis. 
(iv) određivanje bilo koje od mnoštva prosječnih vrijednosti izračunatih pomoću (iii) da bude apsorbancija za provođenje analize uzorka. 10.
The pharmaceutical composition according to claim 15 which is a PDE9 inhibitor. The pharmaceutical composition according to claim 15 for increasing the intracerebral cGMP concentration. 
Farmaceutski pripravak prema zahtjevu 15 naznačen time da je za uporabu u postupku povećanja intracerebralne koncentracije cGMP.
The E. coli host cell of claim 1, wherein nucleic acid encoding the anti-VEGF antibody or the anti-VEGF antibody fragment is selected from the group consisting of nucleic acid encoding the amino acid sequence of SEQ ID NO:46 and nucleic acid encoding the amino acid sequence of SEQ ID NO:47. 
Postupak prema patentnom zahtjevu 12, naznačen time, da je nukleinska Kiselina koja kodira anti-MET protutijelo ili fragment anti-MET protutijela odabrana iz skupine koju čine nukleinska kiselina koja kodira aminokiselinsku sekvencu ID BR: SEK.:50, nukleinska kiselina koja kodira aminokiselinsku sekvencu ID BR.
A pharmaceutical composition comprising a therapeutically-effective amount of the compound as claimed in claim 1, or a salt or ester thereof, and a pharmaceutically acceptable carrier or diluent. 
Farmaceutski pripravak koji sadrži terapijski učinkovitu količinu spoja prema bilo kojem od prethodnih zahtjeva, ili njegovu sol ili ester, i farmaceutski prikladan nosač ili punilo.
reacting the compound of the Formula V with tosylchloride in situ to form a sulphonate ester in the presence of a suitable base and toluene to form the compound of the Formula II. 
(e) reakciju spoja formule V sa tosilkloridom in situ sa svrhom dobivanja sulfonatnog estera u prisutnosti prikladne baze i toluena sa svrhom dobivanja spoja sa formulom JI.
The salt of claim 2, characterized by 2-theta diffraction angle absorption bands obtained from an X-ray powder diffraction pattern of the same or essentially the same as 19.81, 28.63 and 14.64 degrees. 
Sol prema zahtjevu 2, naznačena time što su 2-theta kutovi difrakcije apsorpcijskih vrpci, koje su dobivene rendgenskom difrakcijom praška, jednaki ili u biti jednaki 19.81, 28.63 i 14.64 stupnjeva.
The THF was removed by evaporation, and the residue washed with light petroleum (b.p. 60-80°) to remove mineral oil. 
THF se odvoji isparavanjem, i ostatak se ispere s lakim petrolejem (t.vrenja 60-80%)tako da se odvoji mineralno ulje.
A nucleic acid encoding a fusion protein comprising (a) a human a-N-acetylglucosaminidase (Naglu) protein comprising amino acids 24-743 of SEQ ID NO: 1, (b) an IGF-II peptide tag with at least 85% amino acid sequence identity to amino acids 8-67 of SEQ ID NO: 5, and (c) a spacer peptide located between the Naglu protein and the IGF-II peptide tag, wherein the spacer peptide comprises an amino acid sequence selected from the group consisting of 
Ciljani terapeutski fuzijski protein koji sadrži (a) lizosomski enzim, (b) peptidnu oznaku koja ima sekvencu aminokiseline koja je najmanje 70% identična s aminokiselinama 8-67 zrelog ljudskog IGF-II i (c) peptid razmaknice između lizosomskog enzima i peptidne oznake IGF-II, pri čemu peptid razmaknice sadrži sekvencu aminokiseline GAPGGGSPAPAPTPAPAPTPAPAGGGPSGAP (SEQ ID NO:51).
The kit of claim 11, further comprising a syringe comprising a first barrel and a second barrel, wherein the first barrel is loaded with a topical anesthetic and the second barrel is loaded with a carrier, and a static mixer adapted to be coupled to a syringe. A kit, comprising: 
Komplet iz patentnog zahtjeva 12, nadalje obuhvaća špricu koja sadrži prvu zapremninu (820) i drugu zapremninu (830), pri čemu je prva zapremnina napunjena topikalnim anestetikom i druga zapremnina je napunjena nosačem, i statičko mješalo (860) prilagođeno za povezivanje sa špricom.
A compound of Formula (IV) or its N-oxide or a pharmaceutically acceptable salt thereof: wherein 
Spoj s Formulom (IV) ili njegov N-oksid ili njegova farmaceutski prihvatljiva sol: [image] naznačen time da A je O ili CH2;
Apparatus according to any of claims 1 to 3, wherein the associator (252) is configured such that the predetermined scan order depends on the positions of the significant transform coefficients indicated by previously extracted and associated first-type syntax elements. 
Uređaj prema bilo kojem od zahtjeva 1 do 3, naznačen time, da je pridruživač (252) konfiguriran tako, da predodređeni red skeniranja ovisi od pozicija signifikantnih koeficijenata transformacije koji su prikazani putem prethodno izvučenih 1 pridruženih elemenata sintakse prvog tipa.
thawing the frozen microbiota restoration therapy composition; packaging the sample bag in an insulated packaging system; and 
pakiranje vrećice za uzorke u sustav za izolirano pakiranje; i transport pakirane vrećica za uzorke u ustanovu za liječenje.
A compound according to claim 1, wherein the compound is 3,4-dihydroxy-3',4'-dimethylbiphenyl-2,6-dicarbonitrile. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je spoj 3,4-dihidroksi-4'-proplbifenil-2,6-dikarbonitril.
Based on the solubility/miscibility/range-finding cytotoxicity (ATP) assay results, six concentrations were selected for testing in the full cytogenetics study. Test Article Concentrations 
Na temelju rezultata (ATP) testa topljivosti/miješanja/nalaženja opsega citotoksičnosti, šest koncentracija je izabrano za testiranje u potpunoj citogenetičkoj studiji.